Top-News
Professionelle Dienstleistungen Schweiz

Relief Therapeutics SA Aktie

Aktie
WKN:  A3EFB5 ISIN:  CH1251125998 US-Symbol:  RLFTF
5,9317 €
-0,8221 €
-12,18%
6,45 $ 31.10.24
Handeln Depot/Watchlist
Aktienanzahl *
11,01 Mio.
Marktkapitalisierung *
74,72 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.06.2024

Relief Therapeutics SA News

06.10.22 - DGAP
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. 06-Oct-2022 / 07:00 CET/CEST Release of an ad ...
03.10.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
Relief Therapeutics Holding SA / Key word(s): Patent Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit ...
22.09.22 - DGAP
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa ...
15.09.22 - DGAP
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Relief Therapeutics Holding SA / Key word(s): Interim Report Relief Reports Half-Year 2022 Results and Provides Corporate Update 15-Sep-2022 / 07:00 CET/CEST Release of an ...
12.09.22 - DGAP
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum 12.09.2022 / 07:05 CET/CEST Relief ...
07.09.22 - DGAP
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference 07.09.2022 / 07:00 ...
24.08.22 - DGAP
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission 24-...
22.08.22 - DGAP
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation 22-Aug-...
17.08.22 - DGAP
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access 17-Aug-2022 / 07:00 CET/CEST Release of ...
12.08.22 - DGAP
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan ...
03.08.22 - DGAP
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil) 03-...
28.07.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple ...
28.07.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ...
21.07.22 - DGAP
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F 21-Jul-2022 / 07:00 CET/CEST ...
18.07.22 - DGAP
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium ...
18.07.22 - DGAP
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine 18-Jul-2022 / ...
13.07.22 - DGAP
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Relief Therapeutics Holding SA / Key word(s): Acquisition Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the ...
08.07.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Relief Therapeutics Holding SA / Key word(s): Patent Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) ...
04.07.22 - DGAP
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and ...
04.07.22 - DGAP
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use ...

Newssuche

Videos

newspaper
31.10.24 -9,97%
Technical Trading: 83% Trefferquote für diesen Trade
Nasdaq Long Typ: Turbo Open End WKN: VM433C Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

1.000 % Chance
Desert Gold Ventures Inc.
0,0465 €
-15,5%
Desert Gold Ventures Inc. Chart
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Mehr zur Aktie »